Microcap biotech Ocera craters on a PhIIb failure for hepatic encephalopathy
Ocera $OCRX has joined the growing lineup of microcap biotechs to experience the crushing effect of a clinical setback. The biotech announced that its lead, and only, drug — ornithine phenylacetate (OCR-002) — failed a Phase IIb trial among hospitalized patients suffering from hepatic encephalopathy.
There was a 17-hour reduction in time to an improvement in HE symptoms, compared to the placebo arm. But that was not statistically significant and underwhelmed the analysts following this company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.